News | Heart Valve Technology | April 17, 2024

CPR-Therapeutics, Inc. Names Mike Black as Chief Strategy Officer

Mike Black

Mike Black


April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer.

CPR Therapeutics, Inc. is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is one of the leading causes of sudden death worldwide and there are currently no devices more effective than manual chest compressions. Intact survival after cardiac arrest is below 10% in most communities.

Dave Gaddy, CPR Therapeutic’s CEO said “We could not be more excited to have Mike’s expertise. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. He was CEO of Advanced Circulatory Systems Inc. (ACSI), one of the few start-ups to innovate significantly in CPR. He went on to be Vice President of Global Customer Experience at ZOLL Medical, a leading strategic company in EMS that acquired ACSI in 2015.”

Asked to share his perspective on CPR-T, Mike responded “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Dr. Paradis, CPR-T’s Founder and Chief Medical Officer added: “Mike is a great fit for helping our start-up company take on one of medicine’s most intractable problems – improving the efficacy of CPR. I genuinely believe our chances for success go up significantly having Mike in this important role.”

For more information: www.cprtherapeutics.com


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now